Results 211 to 220 of about 317,398 (334)

Post‐Translational Modifications in Cilia and Ciliopathies

open access: yesAdvanced Science, EarlyView.
This review synthesizes current understanding of post‐translational modifications (PTMs) in ciliary proteins and emphasizes their roles in ciliary formation, homeostasis, and signaling. This review also discusses the implication of PTM dysregulation in ciliopathies and explores therapeutic strategies targeting PTM‐modifying enzymes.
Jie Ran, Jun Zhou
wiley   +1 more source

Editorial: Molecular and Cellular Mechanisms in Reproduction and Early Development

open access: yesFrontiers in Cell and Developmental Biology, 2019
Rafael A. Fissore   +4 more
doaj   +1 more source

HISTONES AND DIFFERENTIATION [PDF]

open access: yesProceedings of the National Academy of Sciences, 1963
openaire   +3 more sources

LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
In SETD2‐mutant ccRCC, the original LEDGF recognition of the H3K36me3 regulatory axis no longer exists. LEDGF interacts with CARM1‐dependent H3R17me2a regulating the transcription of key enzymes in the de novo synthesis pathway. The abnormally elevated LEDGF leads to the accumulation of purine nucleotides in SETD2‐mutant ccRCC, thereby satisfying the ...
Yuwei Zhang   +11 more
wiley   +1 more source

Small RNA Toxin‐Assisted Evolution of GC‐Preferred ErCas12a for Enhanced Genome Targeting Range

open access: yesAdvanced Science, EarlyView.
ErCas12a is engineered to target GC‐rich PAMs using a small RNA toxin‐aided positive screening system. The resulting variant, enErCas12a, exhibits an expanded PAM profile and facilitates efficient gene editing in both bacterial and mammalian cells, while preserving high targeting specificity for both canonical and non‐canonical PAM targets.
Zehua Chen   +8 more
wiley   +1 more source

Metabolism of Histones of Brain and Liver

open access: hybrid, 1966
R. S. Piha   +2 more
openalex   +1 more source

Home - About - Disclaimer - Privacy